Drugs / DE-109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02251938 | Sep 2014 → Nov 2017 | posterior uveitis | Santen Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01358266 Comparator | May 2011 → Sep 2016 | posterior uveitis | Santen Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DE-109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01358266 ↗ |
| Route | Intravitreal | “intravitreal injections of DE-109 ophthalmic solution” NCT01358266 ↗ |